Coronary recanalization rates and changes in the coagulation and fibrinolysis system were evaluated in a randomized fashion in patients with acute myocardial infarction after intracoronary administration of single-chain urokinase-type plasminogen activator (pro-urokinase: GE-0943) or urokinase. Three groups of patients were studied: group H (n=50), 6,000 units pro-urokinase i.c.; group L (n=44), 3,000 units pro-urokinase i.c.; and group U (n=54), 960,000 IU urokinase i.c. Coronary recanalization rates determined angiographically after 45 minutes of intracoronary infusion averaged 90% in group H, 59% in group L, and 61% in group U. The differences were statistically significant between group H and the latter two groups. Pro-urokinase affected plasma proteins of the fibrinolytic system to a lesser degree than urokinase. Bleeding complications were present in one patient in group L, in none in group H, and in five in group U. Thus, intracoronary administration of 6,000 units pro-urokinase is more effective in coronary thrombolysis and causes less systemic fibrinogenolysis than intracoronary administration of urokinase. (Circulation 1988;78:899-905) Rapid and effective dissolution of intracoronary thrombi by systemic or selective infusion of thrombolytic agents has been demonstrated convincingly in many clinical studies. 
arteries in 1982 .11 In 1984 randomized doubleblinded, placebo-controlled study was started to assess early recanalization of infarct-related vessels with intracoronary urokinase in patients with acute myocardial infarction. 12 The patency rate was 74% for the urokinase group and 17% for the placebo group. However, urokinase possesses little specific affinity for fibrin and, therefore, will activate both circulating and fibrin-bound plasminogen, possibly resulting in serious bleeding complications.
Single-chain urokinase-type plasminogen activator (pro-urokinase: GE-0943) 13 The amidolytic activity of pro-urokinase was determined with S-2444, which is a chromogenic substrate for urokinase, before or after activation by plasmin treatment. The amounts of contamination by urokinase in the pro-urokinase preparations were 0% from the amidolytic activities of pro-urokinase preparations before and after activation by plasmin treatment. Three hundred units pro-urokinase (latent activity) described in this paper was estimated to be equivalent to 1 x l05 LU urokinase. Both study drugs were prepared by the Green Cross Corporation, Osaka, Japan, and were identical in appearance.
Study Design
The study comprised the following three groups of patients: group H, four vials of 1,500 units pro-urokinase, 6,000 units in total, were infused during the treatment; group L, four vials of 750 units pro-urokinase, 3 ,000 units in total, were infused during the treatment; and group U, four vials of 240,000 IU urokinase, 960,000 IU in total, were infused during the treatment. Figure 1 and Table 2 Our previous results20 also showed that prourokinase was an effective thrombolytic and was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown, or bleeding. Pro-urokinase does not significantly activate plasminogen in plasma in the absence of fibrin, but the addition of a fibrin clot results in efficient fibrinolysis without fibrinogenolysis.21 In this study, a low dose of pro-urokinase had no significant fibrinolytic effect except on euglobulin lysis time. However, a high dose induced a slight increase in fibrin(ogen) degradation products and a reduction of euglobulin lysis time and a2-plasmin inhibitor. Urokinase showed much more significarnt generalized effects on the fibrolytic system.
Bleeding complications were seen in five patients (9%) in group U, but in only one (2.1%) in group L, and in none in group H. Bleeding complications seen in group L occurred after postinvestigational treatment with additional heparin (10,000 IU) and urokinase (240,000 IU i.c.). Furthermore, because no bleeding complications were seen in group H, even after 9,000 units pro-urokinase was administered to four patients (unpublished data from our laboratory), it is unlikely that the current low dose of pro-urokinase induced hemorrhagic complications. The turnover and clearance of pro-urokinase in rabbits and squirrel monkeys demonstrates a rapid initial half-life of about 3 minutes. The main mechanism of removal from circulation is hepatic clearance. 22, 23 In humans, a biphasic disappearance rate of natural pro-urokinase with an initial half-life of 6 minutes in plasma has been found. 24 In this study, the reinfarction rate during the initial 7 days was low, but the use of prolonged infusion of prourokinase for further reduction of residual stenosis and to prevent restenosis merits consideration.
In a rabbit jugular vein thrombosis preparation, significant synergism between tissue-type plasminogen activator and pro-urokinase was observed. 25 Preliminary results indicated that tissue-type plasminogen activator and pro-urokinase also act synergically in patients with acute myocardial infarction. 26 Low doses of tissue-type plasminogen activator (10 mg) and pro-urokinase (3 mg) were used in the given combination, and coronary reperfusion was obtained within 50 minutes. This synergism was not associated with systemic fibrinolytic breakdown. The combined use of synergic thrombolytic agents may permit a reduction of total administered doses to one fourth of the dose currently used for each agent alone and further decrease the risk of concomitant fibrinogen breakdown,27 but further investigation will be required for confirmation. 
